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Study of familial hypercholesterolemia [FH) has 
yielded information about the low-density lipoprotein 
(LDL) receptor pathwayl and has had heuristic value 
in the understanding of the role of lipoproteins in hu-
man atherosclerosis.2 Treatment of FH by diet, drugs, 
plasmapheresis and portacaval shunt has resulted in 
mild to moderate reductions in total and LDL choles-
terol concentrations in the plasma of these patients.2 
However, patients with almost no residual LDL recep-
tor function are less responsive to these therapies, and 
symptomatic atherosclerotic cardiovascular disease 
will progress.3 Continued atherogenesis is most likely 
due to the inability of therapy to normalize plasma 
lipoprotein levels. Because the LDL receptor abnor-
mality present in skin fibroblasts in these patients was 
also found in homozygous FH hepatic membranes4 
and, more recently, in cultured FH hepatocytes,5 we 
proposed that liver transplantation would be of benefit 
in this disease. The first use of liver transplantation to 
treat FH was with combined heart-liver transplanta-
tion, and as predicted, the plasma LDL cholesterol 
concentrations fell. 6 The present case is the second 
liver transplantation in FH to be reported. 
At age 18 months a yellowish xanthoma was first 
detected on the left ankle of patient V.P. Subsequent 
evaluation of blood cholesterol levels of the entire 
family was consistent with diagnosis of homozygous 
FH. At age 5 years, in addition to following a low-fat, 
low-cholesterol diet, he was started on a cholestyra-
mine regimen of 3 packets twice daily, to which 500 
mg nicotinic acid was added at age 9 years. Despite 
this treatment, the number and size of xanthomas pro-
gressed and the patient was referred to the National 
Institutes of Health for evaluation and treatment at 
age 11. Physical examination of the child was remark-
able for diffuse, marked, yellow xanthomas on the 
elbows, hands, knees and buttocks, as well as Achilles 
tendon xanthomas. A 3/6 systolic ejection murmur at 
the cardiac base, bilateral 416 carotid artery bruits and 
216 femoral artery bruits were noted. Over a 10-
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month period, the patient was sequentially treated 
with each of the following regimens for 2-month peri-
ods: cholestyramine, 12 g/ day; cholestyramine, 12 
g/ day, + nicotinic acid, 3 g/ day; and cholestyramine, 
12 g/ day, + nicotinic acid, 3 g/ day, + mevinolin, 40 
mg/ day. Despite treatment, new-onset angina devel-
oped (characterized by exertional throat pain) and the 
patient had a right parietal cerebrovascular accident. 
Biweekly 3-liter plasma exchanges were instituted af-
ter the patient's neurologic recovery while arrange-
ments for liver transplantation were undertaken. Liv-
er transplantation was performed at the Children's 
Hospital of Pittsburgh on 6 November 1985. Subse-
quent cyc1osporine (400 mg/day) and prednisone (10 
mg/day) immunosuppression therapy has been suc-
cessful in maintaining normal hepatic function. 
Patient V.P. clearly manifested the biochemical 
and genetic characteristics of homozygous FH (Table 
I). The total and LDL cholesterol levels were more 
than 6- and 9.B-fold normal, respectively, in the pro-
band and 1.5- to 2-fold the upper limits of normal for 
both of his parents and for the proband's sibling. 
Achilles tendon xanthomas were evident in all family 
members and both the proband and his father had 
exertional angina and exercise tolerance test results 
that indicated presence of coronary artery disease. 
Skin fibroblasts were cultured from the patient and 
both of his parents and the LDL receptor activities 
established the diagnosis of FH in this family. 
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FIGURE 1. The eHects of various treatment regimens on the plasma 
lipid and lipoprotein concentrations In homozygous familial hyper-
cholesterolemia. Error bars Indicate the mean ± standard error of 
the mean of 3 to 5 replicate samples during the Indicated treatment 
regimen. To convert thesa values to mlilimoies per IHer, multiply the 
value by 0.026. 
706 BRIEF REPORTS 
TABLE I Biochemical Characterization of Familial Hypercholesterolemia In the Proband and His 
Family 
Plasma Cholesterol Concentration (mg/dl) Achilles 
Age Tendon % Normal Fibroblast 
(yr) Total VLDL LDL HDL CAD Xanthoma Receptor Activity 
Proband 11 1,277 107 1,153 17 + + <3% 
Mother 35 405 58 288 59 0 + 58% 
Father 38 436 9 381 46 + + 58% 
Brother 15 374 29 280 65 0 + NO 
·The ability of 200 "g of LDl proteln/ml to stimulate esterification of "CoOleate In 3 normal fibroblast cell lines 
was 10,915 ± 2,912 dpm/mg cell protein/hour and Is defined as 100% activity. 
To convert cholesterol values to millimoies per liter, multiply the value by 0.026. 
CAD = coronary artery disease as Indicated by angina and a positive exercise stress response; HDL = high-
density lipoprotein cholesterol; LDL = low-density lipoprotein cholesterol; NO = not determined; VLDL = very low 
density lipoprotein cholesterol. 
PRE-TRANSPLANT 2 MONTHS POST-TRANSPLANT 
The effects of the different treatment regimens on 
plasma lipoprotein concentrations are illustrated in 
Figure 1. The addition of niacin and mevinolin to the 
cholestyramine regimen had incremental effects and 
the 3-drug regimen reduced the total cholesterol level. 
by 56% and LDL level by 59% and increased the high-
density lipoprotein (HDL) concentration by 53% , 
Therefore, the total cholesteroIlHDL cholesterol ratio 
was reduced from 70 to 20, Although this response to 
drug treatment was good, and better than that usually 
achieved in receptor-negative FH,7 total and LDL cho-
lesterol concentrations of 520 and 461 mg/dl, respec-
tively, would still be anticipated to be associated with 
an increased risk of premature cardiovascular disease. 
Plasma exchange was also used to treat this pa-
tient's hyperlipoproteinemia because it has been an 
effective procedure for homozygous FH,2 Biweekly 3-
liter exchanges reduced postpheresis total and LDL 
cholesterol concentrations by 66% and 67%, respec-
tively; HDL cholesterol concentrations were not af-
fected by this therapy. By increasing the frequency of 
exchanges. the rebound prepheresis hyperlipidemia 
may have been attenuated. Had long-term plasma ex-
change been available to this patient at his home in 
Greece. addition of medication to the exchange regi-
men would have been a serious consideration. 
6 MONTHS 
POST-TRANSPLANT 
FIGURE 2. Regression of tuber-
ous xanthomas of the hands and 
elbows 2 and 6 months after liver 
transplantatlon_ Cyclosporlne-In-
duced hirsutism Is also evident by 
6 months after transplantatlon_ 
Liver transplantation was the most effective means 
of altering plasma lipoprotein concentrations in this 
patient. The striking reduction in total (76%) and LDL 
(83%) cholesterol concentrations was paralleled by a 
194% increase in the HDL cholesterol concentration. 
Therefore, the total cholesteroIlHDL cholesterol ratio 
fell from 70 at baseline to 5.7 after transplantation. 
This marked effect on plasma lipoprotein metabolism 
has already had an effect on tissue deposition of lipid 
(Fig. 2). Xanthoma regression with treatment of homo-
zygous FH usually is a slow process and it is difficult to 
appreciate until after 1 to l Yz years of treatment? Only 
2 months after transplant xanthoma regression was 
evident, and nearly total regression was seen in many 
of the xanthomas 5 to 6 months after transplantation. 
At this time we can only speculate as to the effect of 
liver transplantation on possible cardiovascular ather-
oma regression. However, unlike the first liver trans-
plantation for this condition, which was combined 
with cardiac transplantation,S detailed cardiovascular 
evaluations will be possible to assess the impact of 
liver transplantation on the atherosclerotic process. 
1. Brown MS. Goldstein JL. A receptor-mediated pathway for cholesterol 
homeostasis. Science 1986;232:34-47. 
2. Goldstein JL. Brown MS. Familial Hypercholesterolemia. In: Stanbury lB, 
Wyngaarden lB, Fredrickson DS, Goldstein lL. Brown MS. eds. The Meta-
March 1. 1987 THE AMERICAN JOURNAL OF CARDIOLOGY Volume 59 707 
bolic Basis of Inherited Disease. New York: McGraw Hill. 1983:672-712. 
3. Sprecher DL. Schaefer EJ. Kent KM. Gregg RE. Zech LA. Hoeg JM. 
McManus B. Roberts we. Brewer HB Jr. Cardiovascular features of homozy-
gous familial hypercholeslerolemia: analysis of 16 patients. Am 1 Cardial 
1984;54:20-30. 
4. Haeg jM. Demasky SJ Jr. Gregg RE. Schaefer EJ. Brewer HB Jr. Hepatic 
receptors far low density lipoproteins and apolipopratein E are genetically 
and physiologically distinct in man. Science 1985;227:759-761. 
5. Hoeg 1M. Edge SB. Oemosky SJ Jr. Starzl TE. Triche T. Gregg RS. Brewer 
HB Jr. Metabolism of low density lipoproteins by cultured hepatocytes from 
normal and homozygous familial hypercholesterolemic subjects. Biochem 
Biaphys Acta 1986;876:647-657. 
6. Starzl TE. Bilheimer OW. Bahnsan HT. Shaw BW Jr. Hardesty RL. Griffith 
BP. Iwatsuki S. Zitelli BI. Gartner J Jr. Malatack II. Urbach AH. Heart liver 
transplantatian in a potient with familial hypercholesterolemia. Lancet 
1984;1:1382-1383. 
7. Sprecher DL. Haeg JM. Schaefer EJ. Zech LA. Gregg RE. Lakatos E. Brewer 
HB Jr. The association of LDL receptor activity. LDL cholesterol level. and 
clinical course in homozygous familial hypercholesterolemia. Metabolism 
1985;34:294-299. 
